Positive News SentimentPositive NewsNASDAQ:RNAC Cartesian Therapeutics (RNAC) Stock Price, News & Analysis $6.46 +0.18 (+2.87%) Closing price 04:00 PM EasternExtended Trading$6.46 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cartesian Therapeutics Stock (NASDAQ:RNAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cartesian Therapeutics alerts:Sign Up Key Stats Today's Range$6.13▼$6.5550-Day Range$6.08▼$10.4952-Week Range$5.60▼$11.00Volume118,818 shsAverage Volume194,756 shsMarket Capitalization$195.45 millionP/E RatioN/ADividend YieldN/APrice Target$32.60Consensus RatingModerate Buy Company Overview Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s platform is designed to program a patient’s own immune cells with messenger RNA, enabling the development of cell therapies that are intended to provide targeted treatment without permanent genetic modification. Cartesian’s lead product candidate is Descartes-08, an autologous CAR T-cell therapy that targets B-cell maturation antigen (BCMA). The therapy is being developed for generalized myasthenia gravis, a chronic autoimmune disorder in which antibodies interfere with communication between nerves and muscles. Unlike conventional viral-vector CAR T-cell therapies, Descartes-08 uses mRNA to temporarily direct the activity of the engineered cells. The company is also evaluating its mRNA cell therapy technology in other autoimmune and immune-mediated diseases. Cartesian has advanced its programs through clinical development and has conducted studies primarily in the United States. The company is headquartered in Gaithersburg, Maryland, and is led by President and Chief Executive Officer Carsten Brunn, Ph.D.AI Generated. May Contain Errors. Read More Cartesian Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreRNAC MarketRank™: 2.40092939202 of 5 starsCartesian Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 579th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCartesian Therapeutics has a consensus price target of $32.60, representing about 404.6% upside from its current price of $6.46.Amount of Analyst CoverageCartesian Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cartesian Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cartesian Therapeutics are expected to decrease in the coming year, from ($3.15) to ($4.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cartesian Therapeutics is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cartesian Therapeutics is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cartesian Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.87% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 11.73, which indicates bearish sentiment.Change versus previous monthShort interest in Cartesian Therapeutics has recently increased by 1.05%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCartesian Therapeutics does not currently pay a dividend.Dividend GrowthCartesian Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentCartesian Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cartesian Therapeutics this week, compared to 3 articles on an average week. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders37.20% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cartesian Therapeutics' insider trading history. Receive RNAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNAC Stock News HeadlinesCartesian Therapeutics, Inc. (RNAC) - What Are Brokerages Saying About This Stock?October 18, 2026 | americanbankingnews.comCartesian Therapeutics Announces New Employment Inducement GrantsOctober 2, 2026 | globenewswire.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 27 at 1:00 AM | Weiss Ratings (Ad)Cartesian Reports Positive Phase 2 Retreatment Data For Descartes-08September 29, 2026 | rttnews.comCartesian's Descartes-08 Shows Durable Responses In Myasthenia GravisSeptember 29, 2026 | rttnews.comCartesian Therapeutics Reports Positive Retreatment Data for Descartes-08 in Generalized Myasthenia GravisSeptember 29, 2026 | quiverquant.comQCartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia GravisSeptember 29, 2026 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantsSeptember 8, 2026 | globenewswire.comSee More Headlines RNAC Stock Analysis - Frequently Asked Questions How have RNAC shares performed this year? Cartesian Therapeutics' stock was trading at $7.21 on January 1st, 2026. Since then, RNAC shares have decreased by 10.4% and is now trading at $6.46. How were Cartesian Therapeutics' earnings last quarter? Cartesian Therapeutics, Inc. (NASDAQ:RNAC) posted its quarterly earnings data on Thursday, August, 6th. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of ($0.88) by $1.34. When did Cartesian Therapeutics' stock split? Shares of Cartesian Therapeutics reverse split on the morning of Friday, April 5th 2024.The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Cartesian Therapeutics IPO? Cartesian Therapeutics (RNAC) raised $75 million in an initial public offering on Tuesday, June 21st 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Cartesian Therapeutics? Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cartesian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include Broadcom (AVGO), Eos Energy Enterprises (EOSE), Immunic (IMUX), Lantern Pharma (LTRN), Micron Technology (MU), NVIDIA (NVDA) and Zymeworks (ZYME). Company Calendar Last Earnings8/06/2026Today10/27/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RNAC's financial health is in the Green zone, according to TradeSmith. RNAC has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RNAC Previous SymbolNASDAQ:RNAC CIK1453687 Webwww.cartesiantherapeutics.com Phone617-923-1400Fax617-924-3454Employees75Year Founded2016Price Target and Rating Average Price Target for Cartesian Therapeutics$32.60 High Price Target$44.00 Low Price Target$16.00 Potential Upside/Downside+404.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($5.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.30 million Net Margins-8,550.65% Pretax Margin-10,906.16% Return on EquityN/A Return on Assets-29.84% Debt Debt-to-Equity RatioN/A Current Ratio7.48 Quick Ratio7.48 Sales & Book Value Annual Sales$1.48 million Price / Sales132.33 Cash FlowN/A Price / Cash FlowN/A Book Value($4.85) per share Price / Book-1.33Miscellaneous Outstanding Shares30,255,000Free Float19,000,000Market Cap$195.45 million OptionableOptionable Beta0.65 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:RNAC) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
